var data={"title":"Leucovorin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Leucovorin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6443?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=leucovorin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Leucovorin: Patient drug information&quot;</a> and <a href=\"topic.htm?path=leucovorin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Leucovorin: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11508393\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Lederle Leucovorin;</li>\n      <li>Leucovorin Calcium Injection;</li>\n      <li>Leucovorin Calcium Injection USP</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187403\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antidote;</li>\n      <li>\n        Chemotherapy Modulating Agent;</li>\n      <li>\n        Rescue Agent (Chemotherapy);</li>\n      <li>\n        Vitamin, Water Soluble</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187366\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b>Because oral absorption is saturable at doses &gt;25 mg, administering single oral doses &gt;25 mg is not recommended (convert to parenteral therapy).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Colorectal cancer, advanced:</b> IV: 200 mg/m<sup>2</sup>/day over at least 3 minutes for 5 days every 4 weeks for 2 cycles, then every 4 to 5 weeks (in combination with fluorouracil) <b>or</b> 20 mg/m<sup>2</sup>/day for 5 days every 4 weeks for 2 cycles, then every 4 to 5 weeks (in combination with fluorouracil).<b> Note:</b> Multiple leucovorin-containing regimens are available for the treatment of colorectal cancer. Refer to appropriate literature/guidelines for additional details.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Folic acid antagonist (eg, trimethoprim, pyrimethamine) overdose:</b> Oral: 5 to 15 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Folate-deficient megaloblastic anemia:</b> IM, IV: &le;1 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>High-dose methotrexate-rescue:</b> Initial: Oral, IM, IV: 15 mg (~10 mg/m<sup>2</sup>); start 24 hours after beginning methotrexate infusion; continue every 6 hours for 10 doses, until methotrexate level is &lt;0.05 micromolar. Adjust dose as follows:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Normal methotrexate elimination (serum methotrexate level ~10 micromolar at 24 hours after administration, 1 micromolar at 48 hours, and &lt;0.2 micromolar at 72 hours):</i> Oral, IM, IV: 15 mg every 6 hours for 60 hours (10 doses) beginning 24 hours after the start of methotrexate infusion</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Delayed late methotrexate elimination (serum methotrexate level remaining &gt;0.2 micromolar at 72 hours and &gt;0.05 micromolar at 96 hours after administration):</i> Continue leucovorin calcium 15 mg (oral, IM or IV) every 6 hours until methotrexate level is &lt;0.05 micromolar</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Delayed early methotrexate elimination and/or acute renal injury (serum methotrexate level &ge;50 micromolar at 24 hours, or &ge;5 micromolar at 48 hours, or a doubling of serum creatinine level at 24 hours after methotrexate administration):</i> IV: 150 mg every 3 hours until methotrexate level is &lt;1 micromolar, then 15 mg every 3 hours until methotrexate level is &lt;0.05 micromolar</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>High-dose methotrexate overexposure:</b> Leucovorin nomogram dosing for high-dose methotrexate overexposure (off-label dosing; generalized dosing derived from reference nomogram figures, refer to each reference [Bleyer 1978; Bleyer 1981; Widemann 2006] or institution-specific nomogram for details):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>At 24 hours:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">For methotrexate levels of &ge;100 micromolar at ~24 hours, leucovorin is initially dosed at 1,000 mg/m<sup>2</sup> IV every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">For methotrexate levels of &ge;10 to &lt;100 micromolar at 24 hours, leucovorin is initially dosed at 100 mg/m<sup>2</sup> IV every 3 or 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">For methotrexate levels of ~1 to 10 micromolar at 24 hours, leucovorin is initially dosed at 10 mg/m<sup>2</sup> IV or orally every 3 or 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>At 48 hours:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">For methotrexate levels of &ge;100 micromolar at 48 hours, leucovorin is dosed at 1,000 mg/m<sup>2</sup> IV every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">For methotrexate levels of &ge;10 to &lt;100 micromolar at 48 hours, leucovorin is dosed at 100 mg/m<sup>2</sup> IV every 3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">For methotrexate levels of ~1 to 10 micromolar at 48 hours, leucovorin is dosed at 100 mg/m<sup>2</sup> IV every 6 hours <b>or </b>10 mg/m<sup>2</sup> IV or orally to 100 mg/m<sup>2</sup> IV every 3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>At 72 hours:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">For methotrexate levels of &ge;10 micromolar at 72 hours, leucovorin is dosed at 100 to 1,000 mg/m<sup>2</sup> IV every 3 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">For methotrexate levels of ~1 to 10 micromolar at 72 hours, leucovorin is dosed at 10 mg/m<sup>2</sup> IV or orally to 100 mg/m<sup>2</sup> IV every 3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">For methotrexate levels of ~0.1 to 1 micromolar at 72 hours, leucovorin is dosed at 10 mg/m<sup>2</sup> IV or orally every 3 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">If serum creatinine is increased more than 50% above baseline, increase the standard leucovorin dose to 100 mg/m<sup>2</sup> IV every 3 hours, then adjust according to methotrexate levels above.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Follow methotrexate levels daily, leucovorin may be discontinued when methotrexate level is &lt;0.1 micromolar</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Methotrexate overdose (inadvertent)</b> (begin as soon as possible after overdose): Oral, IM, IV: 10 mg/m<sup>2</sup> every 6 hours until the methotrexate level is &lt;0.01 micromolar. If serum creatinine is increased more than 50% above baseline 24 hours after methotrexate administration, if 24 hour methotrexate level is &gt;5 micromolar, or if 48 hour methotrexate level is &gt;0.9 micromolar, increase leucovorin dose to 100 mg/m<sup>2</sup> IV every 3 hours until the methotrexate level is &lt;0.01 micromolar.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Do not administer leucovorin intrathecally; the use of intrathecal leucovorin is not advised (Jardine 1996; Smith 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bladder cancer, neoadjuvant treatment (off-label use):</b> IV, Oral: 15 mg every 6 hours for 4 doses on days 2 and 9, starting 24 hours after each methotrexate dose (in combination with methotrexate, vinblastine, and cisplatin) (Griffiths 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cofactor therapy in methanol toxicity (off-label use):</b> IV: 1 mg/kg (maximum dose: 50 mg) over 30 to 60 minutes every 4 to 6 hours. Therapy should continue until methanol and formic acid have been completely eliminated (Barceloux 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Esophageal cancer, advanced or metastatic (off-label use): </b>IV: 400 mg/m<sup>2</sup> over 2 hours once every 2 weeks (in combination with fluorouracil and irinotecan [FOLFIRI]) until disease progression or unacceptable toxicity (Guimbaud 2014) <b>or</b> 200 mg/m<sup>2</sup> over 2 hours once every 2 weeks (in combination with fluorouracil and oxaliplatin) until disease progression or unacceptable toxicity (Al-Batran 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gastric cancer, advanced or metastatic (off-label use):</b> IV: 400 mg/m<sup>2</sup> over 2 hours once every 2 weeks (in combination with fluorouracil and irinotecan [FOLFIRI]) until disease progression or unacceptable toxicity (Guimbaud 2014) <b>or</b> 200 mg/m<sup>2</sup> over 2 hours once every 2 weeks (in combination with fluorouracil and oxaliplatin) until disease progression or unacceptable toxicity (Al-Batran 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pancreatic cancer, metastatic (off-label use):</b> IV: 400 mg/m<sup>2</sup> over 2 hours once every 2 weeks (in combination with fluorouracil, oxaliplatin, and irinotecan [FOLFIRINOX]) for at least 6 months (Conroy 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pemetrexed toxicity (off-label dose):</b> IV: 100 mg/m<sup>2</sup> once, followed by 50 mg/m<sup>2</sup> every 6 hours for 8 days (used in clinical trial for CTC grade 4 leukopenia &ge;3 days; CTC grade 4 neutropenia &ge;3 days; immediately for CTC grade 4 thrombocytopenia, bleeding associated with grade 3 thrombocytopenia, or grade 3 or 4 mucositis) (Alimta [prescribing information] 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of pyrimethamine hematologic toxicity in HIV-infected patients (off-label use; HHS [OI adult 2015]):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Isosporiasis (<i>Isospora belli</i>):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Treatment: 10 to 25 mg once daily (in combination with pyrimethamine)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Chronic maintenance (secondary prophylaxis): 5 to 10 mg once daily (in combination with pyrimethamine)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Pneumocystis</i> pneumonia (PCP): Prophylaxis (primary and secondary): 25 mg once weekly (in combination with pyrimethamine [with dapsone]) <b>or</b> 10 mg once daily (in combination with pyrimethamine [with atovaquone])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Toxoplasma gondii</i> encephalitis:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Primary prophylaxis: 25 mg once weekly (in combination with pyrimethamine [with dapsone]) <b>or</b> 10 mg once daily (in combination with pyrimethamine [with atovaquone])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Treatment: 10 to 25 mg once daily (in combination with pyrimethamine [with either sulfadiazine, clindamycin, atovaquone, or azithromycin]). <b>Note:</b> May increase leucovorin to 50 to 100 mg/day in divided doses in cases of pyrimethamine toxicity (rash, nausea, bone marrow suppression).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Chronic maintenance (secondary prophylaxis): 10 to 25 mg once daily (in combination with pyrimethamine [with either sulfadiazine or clindamycin]) <b>or</b> 10 mg once daily (in combination with pyrimethamine [with atovaquone])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187385\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=leucovorin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Leucovorin: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b>Because oral absorption is saturable at doses &gt;25 mg, administering single oral doses &gt;25 mg is not recommended (convert to parenteral therapy).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Folic acid antagonist (eg, trimethoprim, pyrimethamine) overdose:</b> Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Folate-deficient megaloblastic anemia:</b> Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>High-dose methotrexate-rescue:</b> Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cofactor therapy in methanol toxicity (off-label use):</b> Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of pyrimethamine hematologic toxicity in HIV-exposed/-positive patients (off-label uses; CDC 2009): </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children &gt;1 month of age: <b>Note:</b> Leucovorin should continue for 1 week after pyrimethamine is discontinued.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Toxoplasmosis (<i>Toxoplasma gondii</i>):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Primary prophylaxis: Oral: 5 mg once every 3 days (in combination with pyrimethamine [with either dapsone or atovaquone])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Secondary prophylaxis: Oral: 5 mg once every 3 days (in combination with pyrimethamine [with either sulfadiazine, atovaquone, or clindamycin])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Treatment (congenital): Oral or IM: 10 mg with every pyrimethamine dose (in combination with either sulfadiazine or clindamycin); treatment duration: 12 months</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Treatment (acquired): Oral: Acute induction: 10 to 25 mg once daily (in combination with pyrimethamine [with either sulfadiazine, clindamycin, or atovaquone]) for &ge;6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents: Refer to adult dosing</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187367\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16160285\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16160286\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187344\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 300 mg/30 mL (30 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg (1 ea); 200 mg (1 ea); 350 mg (1 ea); 500 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection [strength expressed as base, preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg (1 ea); 100 mg (1 ea); 200 mg (1 ea); 350 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg, 10 mg, 15 mg, 25 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187331\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187347\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Due to calcium content, do not administer IV solutions at a rate &gt;160 mg/minute; not intended for intrathecal use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Refer to individual protocols. Should be administered IM, IV push, or IV infusion (15 minutes to 2 hours). Leucovorin should not be administered concurrently with methotrexate. It is commonly initiated 24 hours after the start of methotrexate. Toxicity to normal tissues may be irreversible if leucovorin is not initiated by ~40 hours after the start of methotrexate.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">As a rescue after folate antagonists: Administer by IV bolus, IM, or orally.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Do not administer orally in the presence of nausea or vomiting. Because oral absorption is saturable at doses above 25 mg, administering oral doses &gt;25 mg is not recommended (convert to parenteral therapy).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Combination therapy with fluorouracil: Fluorouracil is usually given after, or at the midpoint, of the leucovorin infusion. Leucovorin is usually administered by IV bolus injection or short (10 to 120 minutes) IV infusion. Other administration schedules have been used; refer to individual protocols.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">For the treatment of methanol toxicity, infuse over 30 to 60 minutes (Barceloux 2002)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187345\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Colorectal cancer, advanced:</b> Injection: Palliative treatment of advanced colorectal cancer to prolong survival (in combination with 5-fluorouracil). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Methotrexate toxicity:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Injection: Rescue agent after high-dose methotrexate treatment in osteosarcoma and to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral:  Rescue agent to diminish toxicity and counteract effects of impaired methotrexate elimination and inadvertent overdoses of folic acid antagonists. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Megaloblastic anemia: </b> Injection: Treatment of megaloblastic anemias due to folic acid deficiency (when oral therapy is not feasible).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25473435\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Adjunctive cofactor therapy in methanol toxicity; Bladder cancer (neoadjuvant treatment); Esophageal cancer (advanced or metastatic); Gastric cancer (advanced or metastatic); Pancreatic cancer (metastatic); Prevention of pyrimethamine hematologic toxicity in HIV-exposed/-positive patients (children); Prevention of pyrimethamine hematologic toxicity in HIV-infected patients (adolescents and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187410\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Leucovorin may be confused with Leukeran, Leukine, LEVOleucovorin</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Folinic acid may be confused with folic acid</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Folinic acid is an error prone synonym and should not be used</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187337\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined. Toxicities (especially gastrointestinal toxicity) of fluorouracil are enhanced when used in combination with leucovorin.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Erythema, pruritus, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Thrombocythemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylactoid reaction, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Wheezing</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187350\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Pernicious anemia and other megaloblastic anemias secondary to vitamin B<sub>12</sub>-deficiency</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5524355\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity, including allergic reactions, anaphylactoid reactions, and urticaria have been reported with leucovorin. Because leucovorin is typically administered in combination with other chemotherapy agents, it may be difficult to determine the causative agent for hypersensitivity reactions. In a series of 44 patients with hypersensitivity to leucovorin-containing regimens, hypersensitivity/infusion reaction to leucovorin was confirmed in 5 patients; reactions also occurred with subsequent rechallenge with LEVOleucovorin (Ure&ntilde;a-Tavera 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizures: Seizures or syncope have been reported (rarely) in patients with cancer receiving leucovorin, usually in association with fluoropyrimidine administration, and most commonly in patients with CNS metastases or other predisposing factors; a causal relationship has not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anemias: Leucovorin is inappropriate treatment for pernicious anemia and other megaloblastic anemias secondary to a lack of vitamin B<sub>12</sub>; a hematologic remission may occur while neurologic manifestations progress.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Leucovorin is excreted renally; the risk for toxicities may be increased in patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fluorouracil: Leucovorin may increase the toxicity of 5-fluorouracil; deaths from severe enterocolitis, diarrhea, and dehydration have been reported (in elderly patients); granulocytopenia and fever have also been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sulfamethoxazole-trimethoprim: Combination of leucovorin and sulfamethoxazole-trimethoprim for the acute treatment of PCP in patients with HIV infection has been reported to cause increased rates of treatment failure.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Administration route: Parenteral administration may be preferred to oral if vomiting or malabsorption is likely. Because oral absorption is saturable at doses above 25 mg, administering oral doses greater than 25 mg is not recommended (convert to parenteral therapy).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: When doses &gt;10 mg/m<sup>2</sup> are required using the powder for injection, reconstitute using sterile water for injection, not a solution containing benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Injection: Due to calcium content, do not administer IV solutions at a rate &gt;160 mg/minute. Not intended for intrathecal use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings and precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Folic acid antagonist overdose: When used for the treatment of accidental folic acid antagonist overdose, administer as soon as possible.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Methotrexate overdose: When used for the treatment of a methotrexate overdose, administer IV leucovorin as soon as possible. Monitoring of the serum methotrexate concentration is essential to determine the optimal dose/duration of leucovorin; however, do not wait for the results of a methotrexate level before initiating leucovorin. It is important to adjust the leucovorin dose once a methotrexate level is known. The dose may need to be increased or administration prolonged in situations in which methotrexate excretion may be delayed (eg, ascites, pleural effusion, renal insufficiency, inadequate hydration). <b>Never administer leucovorin intrathecally.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Methotrexate rescue therapy: Methotrexate serum concentrations should be monitored to determine dose and duration of leucovorin therapy. Dose may need increased or administration prolonged in situations where methotrexate excretion may be delayed (eg, ascites, pleural effusion, renal insufficiency, inadequate hydration). <b>Never administer leucovorin intrathecally. </b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299583\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187338\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9548&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Capecitabine: Leucovorin Calcium-Levoleucovorin may enhance the adverse/toxic effect of Capecitabine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluorouracil (Systemic): Leucovorin Calcium-Levoleucovorin may enhance the adverse/toxic effect of Fluorouracil (Systemic). This effect is associated with the ability of leucovorin or levoleucovorin to enhance the anticancer effects of fluorouracil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluorouracil (Topical): Leucovorin Calcium-Levoleucovorin may enhance the adverse/toxic effect of Fluorouracil (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: Leucovorin Calcium-Levoleucovorin may decrease the serum concentration of Fosphenytoin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glucarpidase: May decrease serum concentrations of the active metabolite(s) of Leucovorin Calcium-Levoleucovorin. Specifically, 6S-5-methyltetrahydrofolateconcentrations may be reduced. Glucarpidase may decrease the serum concentration of Leucovorin Calcium-Levoleucovorin. Management: Avoid leucovorin administration within 2 hours of glucarpidase dosing.  Continue to administer the pre-glucarpidase leucovorin dose for at least the first 48 hours after glucarpidase administration, and dose based on methotrexate concentration thereafter.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PHENobarbital: Leucovorin Calcium-Levoleucovorin may decrease the serum concentration of PHENobarbital. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: Leucovorin Calcium-Levoleucovorin may decrease the serum concentration of Phenytoin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Primidone: Leucovorin Calcium-Levoleucovorin may decrease the serum concentration of Primidone. Additionally, leucovorin/levoleucovorin may decrease concentrations of active metabolites of primidone (e.g., phenobarbital). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Raltitrexed: Leucovorin Calcium-Levoleucovorin may diminish the therapeutic effect of Raltitrexed. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tegafur: Leucovorin Calcium-Levoleucovorin may enhance the adverse/toxic effect of Tegafur. This effect is associated with the ability of leucovorin or levoleucovorin to enhance the anticancer effects of fluorouracil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimethoprim: Leucovorin Calcium-Levoleucovorin may diminish the therapeutic effect of Trimethoprim.  Management: Avoid concurrent use of leucovorin or levoleucovorin with trimethoprim (plus sulfamethoxazole) for <i>Pneumocystis jirovecii</i> pneumonia.  If trimethoprim is used for another indication, monitor closely for reduced efficacy.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187340\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5524281\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Leucovorin is a biologically active form of folic acid. Adequate amounts of folic acid are recommended during pregnancy. Refer to Folic Acid monograph.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5527100\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Leucovorin is a biologically active form of folic acid. Adequate amounts of folic acid are recommended in breast-feeding women. Refer to Folic Acid monograph.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5524286\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Solutions for injection contain calcium 0.004 mEq per leucovorin 1 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187342\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">High-dose methotrexate therapy: Plasma methotrexate concentration; leucovorin is continued until the plasma methotrexate level &lt;0.05 micromolar. With 4- to 6-hour high-dose methotrexate infusions, plasma drug values in excess of 50 and 1 micromolar at 24 and 48 hours after starting the infusion, respectively, are often predictive of delayed methotrexate clearance.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluorouracil therapy: CBC with differential and platelets, liver function tests, electrolytes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187334\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Leucovorin calcium is a reduced form of folic acid, leucovorin supplies the necessary cofactor blocked by methotrexate. Leucovorin actively competes with methotrexate for transport sites, displaces methotrexate from intracellular binding sites, and restores active folate stores required for DNA/RNA synthesis. Stabilizes the binding of 5-dUMP and thymidylate synthetase, enhancing the activity of fluorouracil. When administered with pyrimethamine for the treatment of opportunistic infections, leucovorin reduces the risk for hematologic toxicity (HHS [OI adult 2015]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Methanol toxicity treatment: Formic acid (methanol&rsquo;s toxic metabolite) is normally metabolized to carbon dioxide and water by 10-formyltetrahydrofolate dehydrogenase after being bound to tetrahydrofolate. Administering a source of tetrahydrofolate may aid the body in eliminating formic acid (Barceloux 2002).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187349\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral, IM: Well absorbed </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Intestinal mucosa and hepatically to 5-methyl-tetrahydrofolate (5MTHF; active) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Saturable at oral doses &gt;25 mg; 25 mg (97%), 50 mg (75%), 100 mg (37%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: ~4 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: Oral: ~2 hours; IV: Total folates: 10 minutes; 5MTHF: ~1 hour; IM: Total folates: 52 minutes; 5MTHF: 2.8 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (primarily); feces</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2524636\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Leucovorin Calcium Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (1): $6.34</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (1): $24.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (1): $28.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">350 mg (1): $31.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (1): $94.45</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Leucovorin Calcium Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (50): $140.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (12): $100.93</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (24): $282.63</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (25): $600.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187352\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acido Folinico/Leucovorina (CL);</li>\n      <li>Antrex (FI, PL, TW);</li>\n      <li>Asovorin (AR);</li>\n      <li>Cafona (TW);</li>\n      <li>Cafonate (LK, PH);</li>\n      <li>Calcium Folinate (NZ);</li>\n      <li>Calciumfolinat Faulding (SE);</li>\n      <li>Calciumfolinat Pharmalink (SE);</li>\n      <li>Calciumfolinat &rdquo;Faulding&rdquo; (DK);</li>\n      <li>Calciumfolinat-Ebewe (PL, TW);</li>\n      <li>Calfonat (DK);</li>\n      <li>Dalisol (MX);</li>\n      <li>Estroquin (PE);</li>\n      <li>Ferbon (KR);</li>\n      <li>Folcasin (ID);</li>\n      <li>Folical (CO);</li>\n      <li>Folina 15 (TW);</li>\n      <li>Folinato de Calcio Dakota Farma (PT);</li>\n      <li>Kalcij-folinat (HR);</li>\n      <li>Kunyrin (VN);</li>\n      <li>Lederfolin (ES, IE, IT);</li>\n      <li>Lederfoline (FR, PT);</li>\n      <li>Ledervorin Calcium (BE, LU, NL);</li>\n      <li>Leucan (ID);</li>\n      <li>Leucocalcin (PY);</li>\n      <li>Leuconolver (VE);</li>\n      <li>Leucovorin (AE, AT, BG, CH, DE, EG, GR, IE, IL, JO, KW, LB, PL, SA, TH, UY);</li>\n      <li>Leucovorin Ca (PL);</li>\n      <li>Leucovorin Calcium (AU, BB, CZ, HK, HN, ID, IN, MY, NZ, TH);</li>\n      <li>Leucovorine Abic (NL);</li>\n      <li>Lifacor (PH);</li>\n      <li>Likelin (CN);</li>\n      <li>Lovorin (PH);</li>\n      <li>Medifolin (PT);</li>\n      <li>Medsavorina (MX);</li>\n      <li>MPL Coverin (PH);</li>\n      <li>Novorin (ID);</li>\n      <li>Nyrin (SG);</li>\n      <li>Refolinon (GB, LU);</li>\n      <li>Rescuvolin (BE, CH, DK, GR, KR, LU, SE, TH, TW);</li>\n      <li>Robin (KR);</li>\n      <li>Rontafur (AR);</li>\n      <li>Tecnovorin (BR, EC)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leucovorin-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18349393\"></a>Al-Batran SE, Hartmann JT, Probst S, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. <i>J Clin Oncol.</i> 2008;26(9):1435-1442.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leucovorin-drug-information/abstract-text/18349393/pubmed\" target=\"_blank\" id=\"18349393\">18349393</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alimta (pemetrexed) [prescribing information]. Indianapolis, IN: Eli Lilly and Co; February 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12216995\"></a>Barceloux DG, Bond GR, Krenzelok EP, et al, &ldquo;American Academy of Clinical Toxicology Practice Guidelines on the Treatment of Methanol Poisoning,&rdquo; <i>J Toxicol Clin Toxicol</i>, 2002, 40(4):415-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leucovorin-drug-information/abstract-text/12216995/pubmed\" target=\"_blank\" id=\"12216995\">12216995</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bleyer WA, &ldquo;New Vistas for Leucovorin in Cancer Chemotherapy,&rdquo; <i>Cancer</i>, 1989, 63(6 Suppl):995-1007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bleyer WA. The clinical pharmacology of methotrexate: new applications of an old drug. <i>Cancer</i>. 1978;41(1):36-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leucovorin-drug-information/abstract-text/342086/pubmed\" target=\"_blank\" id=\"342086\">342086</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bleyer WA. Therapeutic monitoring of methotrexate and other antineoplastic drugs. In Baer DM, Devits WR meds. <i>Interpretations in Therapeutic Drug Monitoring</i>. Chicago, IL: American Society of Clinical Pathology; 1981:169-181.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leucovorin-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19357635\"></a>Centers for Disease Control and Prevention, &ldquo;Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents: Recommendations From CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America,&rdquo; <i>MMWR Recomm Rep</i>, 2009, 58(RR-4):1-207.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leucovorin-drug-information/abstract-text/19357635/pubmed\" target=\"_blank\" id=\"19357635\">19357635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21561347\"></a>Conroy T, Desseigne F, Ychou M, et al; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.<i> N Engl J Med</i>. 2011;364(19):1817-1825.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leucovorin-drug-information/abstract-text/21561347/pubmed\" target=\"_blank\" id=\"21561347\">21561347</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Conroy T, Paillot B, Fran&ccedil;ois E, et al. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. <i>J Clin Oncol.</i> 2005;23(6):1228-1236.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leucovorin-drug-information/abstract-text/15718320/pubmed\" target=\"_blank\" id=\"15718320\">15718320</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21502557\"></a>Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK; International Collaboration of Trialists; Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group); European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group, et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. <i>J Clin Oncol.</i> 2011;29(16):2171-2177.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leucovorin-drug-information/abstract-text/21502557/pubmed\" target=\"_blank\" id=\"21502557\">21502557</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25287828\"></a>Guimbaud R, Louvet C, Ries P, et al. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Federation Francophone de Cancerologie Digestive, Federation Nationale des Centres de Lutte Contre le Cancer, and Groupe Cooperateur Multidisciplinaire en Oncologie) study. <i>J Clin Oncol.</i> 2014;32(31):3520-3526.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leucovorin-drug-information/abstract-text/25287828/pubmed\" target=\"_blank\" id=\"25287828\">25287828</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leucovorin-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jacobsen D and McMartin KE, &ldquo;Methanol and Ethylene Glycol Poisonings. Mechanism of Toxicity, Clinical Course, Diagnosis and Treatment,&rdquo; <i>Med Toxicol</i>, 1986, 1(5):309-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leucovorin-drug-information/abstract-text/3537623/pubmed\" target=\"_blank\" id=\"3537623\">3537623</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jardine LF, Ingram LC, and Bleyer WA, &ldquo;Intrathecal Leucovorin After Intrathecal Methotrexate Overdose,&rdquo; <i>J Pediatr Hematol Oncol</i>, 1996, 18(3):302-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leucovorin-drug-information/abstract-text/8689347/pubmed\" target=\"_blank\" id=\"8689347\">8689347</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lam MS. Extemporaneous compounding of oral liquid dosage formulations and alternative drug delivery methods for anticancer drugs. <i>Pharmacotherapy</i>. 2011;31(2):164-192.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leucovorin-drug-information/abstract-text/21275495/pubmed\" target=\"_blank\" id=\"21275495\">21275495</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leucovorin calcium for injection [prescribing information]. Schaumburg, IL: Sagent Pharmaceuticals; February 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leucovorin calcium tablets [prescribing information]. Columbus, OH: Roxanne Laboratories; December 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leucovorin calcium tablets [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals Corp; March 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Machover D, &ldquo;A Comprehensive Review of 5-Fluorouracil and Leucovorin in Patients With Metastatic Colorectal Carcinoma,&rdquo; <i>Cancer</i>, 1997, 80(7):1179-87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leucovorin-drug-information/abstract-text/9317168/pubmed\" target=\"_blank\" id=\"9317168\">9317168</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McGuire BW, Sia LL, Leese PT, et al, &ldquo;Pharmacokinetics of Leucovorin Calcium After Intravenous, Intramuscular, and Oral Administration,&rdquo; <i>Clin Pharm</i>, 1988, 7(1):52-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leucovorin-drug-information/abstract-text/3257913/pubmed\" target=\"_blank\" id=\"3257913\">3257913</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rustum YM, &ldquo;Modulation of Fluoropyrimidines by Leucovorin: Rationale and Status,&rdquo; <i>J Surg Oncol Suppl</i>, 1991, 2:116-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leucovorin-drug-information/abstract-text/1832538/pubmed\" target=\"_blank\" id=\"1832538\">1832538</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smith SW and Nelson LS, &ldquo;Case Files of the New York City Poison Control Center: Antidotal Strategies for the Management of Methotrexate Toxicity,&rdquo; <i>J Med Toxicol</i>, 2008, 4(2):132-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leucovorin-drug-information/abstract-text/18570175/pubmed\" target=\"_blank\" id=\"18570175\">18570175</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trissel LA, Martinez JF, and Xu QA, &ldquo;Incompatibility of Fluorouracil With Leucovorin Calcium or Levoleucovorin Calcium,&rdquo; <i>Am J Health Syst Pharm</i>, 1995, 52(7):710-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leucovorin-drug-information/abstract-text/7627739/pubmed\" target=\"_blank\" id=\"7627739\">7627739</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ure&ntilde;a-Tavera A, Zamora-Verduga M, Madrigal-Burgaleta R, Angel-Pereira D, Berges-Gimeno MP, Alvarez-Cuesta E. Hypersensitivity reactions to racemic calcium folinate (leucovorin) during FOLFOX and FOLFIRI chemotherapy administrations.<i> J Allergy Clin Immunol.</i> 2015;135(4):1066-1067.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leucovorin-drug-information/abstract-text/25457996/pubmed\" target=\"_blank\" id=\"25457996\">25457996</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Updated September 24, 2015. Accessed September 25, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Van Delden C and Hirschel B, &quot;Folinic Acid Supplements to Pyrimethamine-Sulfadiazine for <i>Toxoplasma encephalitis</i> Are Associated With Better Outcome,&quot; <i>J Infect Dis</i>, 1996, 173(5):1294-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leucovorin-drug-information/abstract-text/8627092/pubmed\" target=\"_blank\" id=\"8627092\">8627092</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Walker SE, Law S, and Puodziunas A, &ldquo;Simulation of Y-Site Compatibility of Irinotecan and Leucovorin at Room Temperature in 5% Dextrose in Water in 3 Different Containers,&rdquo; <i>Can J Hosp Pharm</i>, 2005, 58(4):212-22.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Widemann BC and Adamson PC, &ldquo;Understanding and Managing Methotrexate Nephrotoxicity,&rdquo; <i>Oncologist,</i> 2006, 11(6):694-703.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leucovorin-drug-information/abstract-text/16794248/pubmed\" target=\"_blank\" id=\"16794248\">16794248</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9548 Version 171.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F11508393\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F187403\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F187366\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F187385\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F187367\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F16160285\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F16160286\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F187344\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F187331\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F187347\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F187345\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25473435\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F187410\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F187337\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F187350\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F5524355\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299583\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F187338\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F187340\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5524281\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F5527100\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F5524286\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F187342\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F187334\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F187349\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F2524636\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F187352\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9548|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=leucovorin-patient-drug-information\" class=\"drug drug_patient\">Leucovorin: Patient drug information</a></li><li><a href=\"topic.htm?path=leucovorin-pediatric-drug-information\" class=\"drug drug_pediatric\">Leucovorin: Pediatric drug information</a></li></ul></div></div>","javascript":null}